PE20030121A1 - Derivados de quinazolina como promotores de la liberacion de hormona paratiroides (pt) - Google Patents

Derivados de quinazolina como promotores de la liberacion de hormona paratiroides (pt)

Info

Publication number
PE20030121A1
PE20030121A1 PE2002000517A PE2002000517A PE20030121A1 PE 20030121 A1 PE20030121 A1 PE 20030121A1 PE 2002000517 A PE2002000517 A PE 2002000517A PE 2002000517 A PE2002000517 A PE 2002000517A PE 20030121 A1 PE20030121 A1 PE 20030121A1
Authority
PE
Peru
Prior art keywords
phenyl
isopropyl
isopropil
quinazolin
ona
Prior art date
Application number
PE2002000517A
Other languages
English (en)
Inventor
Rene Beerli
Ruben Alberto Tommasi
Leo Widler
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0114702A external-priority patent/GB0114702D0/en
Priority claimed from GB0114701A external-priority patent/GB0114701D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030121A1 publication Critical patent/PE20030121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/88—Nicotinoylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE COMPUESTOS BICICLICOS DE PREFERENCIA DERIVADOS DE 4-ARIL-2-(1H)-QUINAZOLINONA, DERIVADOS DE 4-ARIL-QUINAZOLINA 2- SUSTITUIDA DE FORMULA I, QUE TIENEN ACTIVIDAD ANTAGONISTA DEL RECEPTOR DE DETECCION DE CALCIO DE PARATIROIDES, DONDE -N(R2)=C(=R4); N=CHR4; NR2-CH(=Y); Y ES O, S; R1 ES OH, SH, HALOGENO, NO2, ALQUILO, ALCOXILO, ALQUENILO, ALQUENILOXILO, ALQUINILO, ENTRE OTROS; R2 ES H, ALQUILO, ARILO, ARILALQUILO, CICLOALQUILO, CICLOALQUILALQUILO, ENTRE OTROS; R3 ES HALOGENO, ALQUILO, ALCOXILO, AMINO; R4' ES CIANO, HALOGENO,. AZIDA (N=N=N), ALQUILO, ALCOXILO, TIOALCOXILO, ARILOXILO, ARILALCOXILO, AMINO PARA EL TRATAMIENTO DE AGOTAMIENTO O RESORCION DE CALCIO. SON COMPUESTOS PREFERIDOS 1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)-6-NITRO-1H-QUINAZOLIN-2-ONA; 6-AMINO-1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)-1H-QUINAZOLIN-2-ONA; 6-DIALILAMINO-1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)-1H-QUINAZOLIN-2-ONA; 6-ALILAMINO-1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)1H-QUINAZOLIN-2-ONA; 6-DIMETILAMINO-1-ISOPROPIL-4-(4-ISOPROPIL-FENIL)-1H-QUINAZOLIN-2-ONA; (2-ISOPROPILAMINO-4,5-DIMETOXI-FENIL-(4-ISOPROPIL-FENIL)-METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A COMPUESTOS DE FORMULA IV DONDE R1' ES H, OH, HALOGENO, ENTRE OTROS; R3' ES ALQUILO; R2" ES ARILALQUILO EXCEPTO LOS COMPUESTOS 1-BENCIL-4-FENIL-6-NITRO-2(1H)-QUINAZOLINA, 1-(2-PIRIDILMETIL)-4-FENIL-6-NITRO-2(1H)-QUINAZOLINA, ENTRE OTROS. TAMBIEN SE REFIERE A PROCESOS PARA LA PREPARACION
PE2002000517A 2001-06-15 2002-06-14 Derivados de quinazolina como promotores de la liberacion de hormona paratiroides (pt) PE20030121A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0114702A GB0114702D0 (en) 2001-06-15 2001-06-15 Organic compounds
GB0114701A GB0114701D0 (en) 2001-06-15 2001-06-15 Organic compounds

Publications (1)

Publication Number Publication Date
PE20030121A1 true PE20030121A1 (es) 2003-04-02

Family

ID=26246197

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000517A PE20030121A1 (es) 2001-06-15 2002-06-14 Derivados de quinazolina como promotores de la liberacion de hormona paratiroides (pt)

Country Status (31)

Country Link
US (1) US8476286B2 (es)
EP (2) EP1401451B1 (es)
JP (2) JP4118801B2 (es)
KR (1) KR100699959B1 (es)
CN (1) CN1516587A (es)
AR (1) AR038658A1 (es)
AT (1) ATE447958T1 (es)
AU (1) AU2002325242B2 (es)
BR (1) BR0210920A (es)
CA (1) CA2449234C (es)
CO (1) CO5550443A2 (es)
CY (1) CY1109767T1 (es)
CZ (1) CZ20033389A3 (es)
DE (1) DE60234341D1 (es)
DK (1) DK1401451T3 (es)
ES (1) ES2336197T3 (es)
HU (1) HUP0400205A3 (es)
IL (2) IL159000A0 (es)
MX (1) MXPA03011626A (es)
MY (1) MY145325A (es)
NO (1) NO326384B1 (es)
NZ (1) NZ529716A (es)
PE (1) PE20030121A1 (es)
PL (1) PL364474A1 (es)
PT (1) PT1401451E (es)
RU (1) RU2302244C2 (es)
SI (1) SI1401451T1 (es)
SK (1) SK287802B6 (es)
TW (1) TWI330179B (es)
WO (1) WO2002102782A2 (es)
ZA (1) ZA200309042B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
AU2007231842B2 (en) * 2002-12-23 2011-04-14 Novartis Ag Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
TWI329628B (en) * 2003-04-23 2010-09-01 Japan Tobacco Inc Casr antagonist
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
GB0511410D0 (en) * 2005-06-03 2005-07-13 James Black Foundation Benzotrizepinone derivatives
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds
GB0610018D0 (en) * 2006-05-19 2006-06-28 James Black Foundation Benzotriazepinone derivatives
KR100974081B1 (ko) * 2008-07-24 2010-08-04 이화여자대학교 산학협력단 착탈식 치아 교정기구
EP2396316B1 (en) * 2009-02-10 2015-07-01 Janssen Pharmaceutica, N.V. Quinazolinones as prolyl hydroxylase inhibitors
TWI496782B (zh) 2009-04-28 2015-08-21 Chugai Pharmaceutical Co Ltd Spiro haloperidone derivatives
MX344109B (es) 2011-10-25 2016-12-05 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
CA2892621C (en) * 2012-12-10 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative
US9993462B2 (en) 2014-06-09 2018-06-12 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1195066A (en) * 1916-08-15 Traction whxel
US1313789A (en) * 1919-08-19 Puanookai h cu
US1353789A (en) * 1920-09-21 Window-venthiator
US1181570A (en) * 1911-03-18 1916-05-02 Churchward Internat Steel Company Alloyed steel.
US1046063A (en) * 1911-12-12 1912-12-03 Frederick H Felt Scale.
US1248428A (en) * 1917-06-26 1917-11-27 James Ferdinand Groom Roberts Cooking apparatus.
US3305553A (en) * 1965-10-18 1967-02-21 Parke Davis & Co 2-aminoquinazoline derivatives
CH487902A (de) * 1966-08-29 1970-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Chinazolinonen
FR6001M (es) * 1966-12-02 1968-04-29
US3723432A (en) * 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
BG16442A3 (bg) * 1967-10-30 1972-11-20 Max Denzer Метод за получаване на нови о-изопропиламинобензофенони
US3923803A (en) * 1968-07-18 1975-12-02 Sumitomo Chemical Co 2(1H)-Quinozalinones and process therefor
GB1251600A (es) 1968-07-18 1971-10-27
DE2037693C3 (de) * 1969-08-02 1975-01-16 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1-Cyclopropylmethyl-2(1 H)-chinazolinonderivate
US3767797A (en) * 1969-08-02 1973-10-23 Sumitomo Chemical Co Novel quinazolinone derivatives as antiinflammatory and analgesic agents
JPS5118423B1 (es) 1970-12-08 1976-06-09
JPS5013271B2 (es) 1971-10-04 1975-05-19
BE790804A (fr) * 1971-11-18 1973-04-30 Sandoz Sa Procede de preparation de derives de la quinazoline
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
JPS5418269B2 (es) * 1972-07-20 1979-07-06
JPS555506B2 (es) * 1972-09-07 1980-02-07
US3997564A (en) * 1973-04-13 1976-12-14 Sandoz, Inc. N-(3,4-methylenedioxy-phenyl)ureas
US4067868A (en) * 1973-04-17 1978-01-10 Sumitomo Chemical Company, Limited Production of quinazolinone compounds
JPS5046680A (es) 1973-08-20 1975-04-25
JPS518287A (en) 1974-07-13 1976-01-23 Sumitomo Chemical Co Kinazorinonjudotaioyobi sonoenno seizoho
JPS5125193A (en) * 1974-08-26 1976-03-01 Sumitomo Chemical Co Kinazorinjudotaino biryoteiryoho
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5271483A (en) * 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CH625512A5 (es) * 1976-12-13 1981-09-30 Sandoz Ag
US4171441A (en) * 1977-09-06 1979-10-16 Sandoz, Inc. Preparation of quinazolin-2(1H)-ones
JPS5795966A (en) 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
TW232013B (es) 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
EP1203761B1 (en) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5773663A (en) * 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones
DE19524398C1 (de) * 1995-07-04 1996-11-21 Adalbert Gubo Verfahren zum Archivieren von Dokumenten
CN1136547C (zh) * 1995-08-22 2004-01-28 松下电器产业株式会社 光盘记录和／或重放装置及设定记录功率及清除功率的方法
JPH11514361A (ja) * 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
JP4530552B2 (ja) * 2001-01-29 2010-08-25 富士通セミコンダクター株式会社 半導体装置及びその製造方法
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7776035B2 (en) * 2004-10-08 2010-08-17 Covidien Ag Cool-tip combined electrode introducer

Also Published As

Publication number Publication date
SK15212003A3 (sk) 2004-08-03
EP1401451B1 (en) 2009-11-11
SK287802B6 (sk) 2011-10-04
NZ529716A (en) 2006-04-28
US8476286B2 (en) 2013-07-02
US20040180912A1 (en) 2004-09-16
NO20035573L (no) 2004-02-16
ES2336197T3 (es) 2010-04-09
HUP0400205A3 (en) 2004-10-28
CO5550443A2 (es) 2005-08-31
TWI330179B (en) 2010-09-11
MXPA03011626A (es) 2004-04-05
WO2002102782A2 (en) 2002-12-27
IL159000A (en) 2009-11-18
NO20035573D0 (no) 2003-12-12
CZ20033389A3 (cs) 2004-08-18
AU2002325242B2 (en) 2006-11-09
ATE447958T1 (de) 2009-11-15
RU2003137571A (ru) 2005-05-10
KR100699959B1 (ko) 2007-03-27
ZA200309042B (en) 2004-05-21
EP1401451A2 (en) 2004-03-31
JP4118801B2 (ja) 2008-07-16
CA2449234A1 (en) 2002-12-27
BR0210920A (pt) 2008-04-08
PT1401451E (pt) 2010-02-18
JP2008214349A (ja) 2008-09-18
MY145325A (en) 2012-01-31
AR038658A1 (es) 2005-01-26
IL159000A0 (en) 2004-05-12
CY1109767T1 (el) 2014-09-10
WO2002102782A3 (en) 2003-05-01
JP2005502605A (ja) 2005-01-27
PL364474A1 (en) 2004-12-13
EP2191832A1 (en) 2010-06-02
KR20040007702A (ko) 2004-01-24
RU2302244C2 (ru) 2007-07-10
NO326384B1 (no) 2008-11-24
CN1516587A (zh) 2004-07-28
DE60234341D1 (de) 2009-12-24
CA2449234C (en) 2011-02-15
SI1401451T1 (sl) 2010-03-31
DK1401451T3 (da) 2010-03-29
HUP0400205A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
PE20030121A1 (es) Derivados de quinazolina como promotores de la liberacion de hormona paratiroides (pt)
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20050762A1 (es) Derivados de bencimidazol
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20020061A1 (es) Fenil sulfamoil carboxamidas sustituidas
PE20010758A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA SUSTITUIDOS POR HETEROALQUILO COMO INHIBIDORES DE QUINASAS p38
PE20030847A1 (es) Aza-arilpiperazinas como ligandos del receptor 5ht2
JP2003508387A5 (es)
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
ATE458483T1 (de) Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
BRPI0412314B8 (pt) composto 3-[2(r)-{hidroxicarbonilpropil-amino}-2-feniletil]-5-(2-flúor-3-metoxifenil)-1-[2-flúor-6-(trifluorometil)benzil]-6-metil-pirimidina-2,4(1h,3h)-diona, composição farmacêutica compreendendo dito composto e uso do mesmo para o tratamento de uma condição relacionada ao hormônio sexual
BRPI0415424A (pt) processo para preparação de composto de aminocrotonila
PE20041040A1 (es) Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1
HUP0000914A2 (hu) 3-Aril-4 (3H)-kinazolinon-származékok atropizomerjei és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
PE20080277A1 (es) Derivados de azaindol espirociclicos y sustituidos
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20020514A1 (es) Aminas heterociclicas y fenilazacicloalcanos sustituidos para el tratamiento del sindrome de piernas inquietas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed